Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.

Daakour S, Hajingabo LJ, Kerselidou D, Devresse A, Kettmann R, Simonis N, Dequiedt F, Twizere JC.

BMC Cancer. 2016 May 26;16:335. doi: 10.1186/s12885-016-2374-2.

2.

Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family.

Revoredo L, Wang S, Bennett EP, Clausen H, Moremen KW, Jarvis DL, Ten Hagen KG, Tabak LA, Gerken TA.

Glycobiology. 2016 Apr;26(4):360-76. doi: 10.1093/glycob/cwv108. Epub 2015 Nov 26.

3.

Control of cell differentiation by mitochondria, typically evidenced in dictyostelium development.

Maeda Y, Chida J.

Biomolecules. 2013 Nov 11;3(4):943-66. doi: 10.3390/biom3040943.

4.

TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.

Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, Iborra F, Pajares MJ, Larrayoz M, Zudaire I, Pio R, Montuenga LM, Harris AL, Gatter K, Pezzella F.

Mol Cancer Res. 2014 May;12(5):660-9. doi: 10.1158/1541-7786.MCR-13-0481. Epub 2014 Feb 24.

5.

The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation.

Gerken TA, Revoredo L, Thome JJ, Tabak LA, Vester-Christensen MB, Clausen H, Gahlay GK, Jarvis DL, Johnson RW, Moniz HA, Moremen K.

J Biol Chem. 2013 Jul 5;288(27):19900-14. doi: 10.1074/jbc.M113.477877. Epub 2013 May 20.

6.

Emerging paradigms for the initiation of mucin-type protein O-glycosylation by the polypeptide GalNAc transferase family of glycosyltransferases.

Gerken TA, Jamison O, Perrine CL, Collette JC, Moinova H, Ravi L, Markowitz SD, Shen W, Patel H, Tabak LA.

J Biol Chem. 2011 Apr 22;286(16):14493-507. doi: 10.1074/jbc.M111.218701. Epub 2011 Feb 24.

7.

No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.

Reijnders CM, Waaijer CJ, Hamilton A, Buddingh EP, Dijkstra SP, Ham J, Bakker E, Szuhai K, Karperien M, Hogendoorn PC, Stringer SE, Bovée JV.

Am J Pathol. 2010 Oct;177(4):1946-57. doi: 10.2353/ajpath.2010.100296. Epub 2010 Sep 2.

8.

Pancreatic reg I binds MKP-1 and regulates cyclin D in pancreatic-derived cells.

Mueller CM, Zhang H, Zenilman ME.

J Surg Res. 2008 Nov;150(1):137-43. doi: 10.1016/j.jss.2008.03.047. Epub 2008 Apr 28.

9.

Multiple osteochondromas.

Bovée JV.

Orphanet J Rare Dis. 2008 Feb 13;3:3. doi: 10.1186/1750-1172-3-3. Review.

10.

Many genes in fish have species-specific asymmetric rates of molecular evolution.

Steinke D, Salzburger W, Braasch I, Meyer A.

BMC Genomics. 2006 Feb 8;7:20.

11.

The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Duncan G, McCormick C, Tufaro F.

J Clin Invest. 2001 Aug;108(4):511-6. Review. No abstract available.

12.

Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity.

Cheung PK, McCormick C, Crawford BE, Esko JD, Tufaro F, Duncan G.

Am J Hum Genet. 2001 Jul;69(1):55-66. Epub 2001 Jun 5.

13.

The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis.

Senay C, Lind T, Muguruma K, Tone Y, Kitagawa H, Sugahara K, Lidholt K, Lindahl U, Kusche-Gullberg M.

EMBO Rep. 2000 Sep;1(3):282-6.

Supplemental Content

Support Center